HC Wainwright Expects Lower Earnings for BioHarvest Sciences

BioHarvest Sciences Inc. (NASDAQ:BHST) – HC Wainwright lowered their FY2027 earnings per share estimates for shares of BioHarvest Sciences in a research report issued on Thursday, April 23rd. HC Wainwright analyst A. Dayal now forecasts that the company will earn $0.04 per share for the year, down from their prior estimate of $0.07. The consensus estimate for BioHarvest Sciences’ current full-year earnings is ($0.34) per share. HC Wainwright also issued estimates for BioHarvest Sciences’ FY2028 earnings at $0.36 EPS, FY2029 earnings at $0.79 EPS and FY2030 earnings at $1.29 EPS.

A number of other brokerages have also recently issued reports on BHST. Roth Mkm started coverage on BioHarvest Sciences in a report on Thursday, February 19th. They issued a “buy” rating and a $10.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of BioHarvest Sciences in a report on Friday, March 27th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, BioHarvest Sciences has a consensus rating of “Hold” and a consensus target price of $12.50.

BioHarvest Sciences Trading Up 0.7%

Shares of BHST opened at $4.38 on Friday. BioHarvest Sciences has a 1 year low of $4.10 and a 1 year high of $12.80. The company has a current ratio of 3.97, a quick ratio of 3.38 and a debt-to-equity ratio of 0.10. The stock has a 50 day simple moving average of $4.38 and a 200-day simple moving average of $6.02. The stock has a market cap of $85.92 million, a PE ratio of -7.18 and a beta of 1.16.

Hedge Funds Weigh In On BioHarvest Sciences

A number of hedge funds have recently modified their holdings of BHST. XTX Topco Ltd acquired a new stake in BioHarvest Sciences during the 4th quarter valued at $173,000. Quadrature Capital Ltd acquired a new stake in BioHarvest Sciences during the 4th quarter valued at $140,000. Osaic Holdings Inc. increased its holdings in BioHarvest Sciences by 5,510.4% during the 4th quarter. Osaic Holdings Inc. now owns 35,233 shares of the company’s stock valued at $183,000 after purchasing an additional 34,605 shares in the last quarter. Evercore Wealth Management LLC acquired a new stake in BioHarvest Sciences during the 4th quarter valued at $724,000. Finally, Marshall Wace LLP acquired a new stake in BioHarvest Sciences during the 4th quarter valued at $110,000.

About BioHarvest Sciences

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.